Bayer v. Mylan (Fed. Cir., September 23, 2025) 2023-2434
This opinion from the United States Court of Appeals for the Federal Circuit concerns a patent infringement appeal case, Bayer Pharma Aktiengesellschaft v. Mylan Pharmaceuticals Inc. The appeal concerns the Patent Trial and Appeal Board's (PTAB) final written decision holding claims of Bayer's U.S. Patent No. 10,828,310, which describes methods using rivaroxaban and aspirin to reduce cardiovascular risk, unpatentable. The Court affirms-in-part and vacates-in-part the PTAB's decision, specifically upholding the unpatentability of claims 1–4, but vacating the judgment for claims 5–8 due to an…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.